Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Background: The biomarkers of immune checkpoint inhibitors (ICIs) efficacy and safety are still urgently needed. As cytokines are easily detected and monitored in circulation, they could be used as potential predictors of response and immune-related adverse events (irAEs) for ICIs therapy. Methods:...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Katarina Mirjačić Martinović, Ana Vuletić, Nevena Tišma Miletić, Irina Besu Žižak, Jelena Milovanović, Suzana Matković, Vladimir Jurišić
Fformat:	Erthygl
Iaith:	English
Cyhoeddwyd:	Elsevier 2023-12-01
Cyfres:	Translational Oncology
Pynciau:	Metastatic melanoma patients BRAF wild type Pembrolizumab Cytokines Monitoring Outcome predictors
Mynediad Ar-lein:	http://www.sciencedirect.com/science/article/pii/S1936523323001857

Eitemau Tebyg

Complete response in a patient with BRAF-mutant metastatic melanoma achieved with the multidisciplinary approach: a case report
gan: Hana Garaj, et al.
Cyhoeddwyd: (2024-01-01)

Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices
gan: Senar Ebinç, et al.
Cyhoeddwyd: (2023-09-01)

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
gan: Wu L, et al.
Cyhoeddwyd: (2021-02-01)

Increased circulating monocyte MDSCs positively correlate with serum Interleukin-10 in metastatic melanoma patients
gan: Katarina Mirjačić Martinović, et al.
Cyhoeddwyd: (2023-04-01)

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives
gan: Dugan MM, et al.
Cyhoeddwyd: (2024-07-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
gan: Polsky David, et al.
Cyhoeddwyd: (2004-12-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
gan: Francesca Consoli, et al.
Cyhoeddwyd: (2020-07-01)

Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study
gan: Jacek Calik, et al.
Cyhoeddwyd: (2024-01-01)

Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease
gan: Xiang Dan, et al.
Cyhoeddwyd: (2024-04-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
gan: I. V. SAMOILENKO, et al.
Cyhoeddwyd: (2017-06-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
gan: Ernesto Rossi, et al.
Cyhoeddwyd: (2023-01-01)

A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [14C] encorafenib in healthy male subjects
gan: Lance Wollenberg, et al.
Cyhoeddwyd: (2023-10-01)

Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report
gan: Bartoušková Marie, et al.
Cyhoeddwyd: (2020-08-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
gan: Justin C. Moser, et al.
Cyhoeddwyd: (2019-12-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
gan: Yu. S. Shakh-Paronyants, et al.
Cyhoeddwyd: (2023-03-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
gan: Dahlia Fedele, et al.
Cyhoeddwyd: (2024-01-01)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
gan: Saba S. Shaikh, et al.
Cyhoeddwyd: (2022-11-01)

Melanoma: BRAFi Rechallenge
gan: Christoforos S. Kosmidis, et al.
Cyhoeddwyd: (2023-05-01)

Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naïve and previously infected individuals
gan: Milena Cavic, et al.
Cyhoeddwyd: (2023-04-01)

MEK inhibitors for the treatment of NRAS mutant melanoma
gan: Sarkisian S, et al.
Cyhoeddwyd: (2018-08-01)

The Human Melanoma Proteome Atlas—Complementing the melanoma transcriptome
gan: Lazaro Hiram Betancourt, et al.
Cyhoeddwyd: (2021-07-01)

Current State of Target Treatment in BRAF Mutated Melanoma
gan: Enrica Teresa Tanda, et al.
Cyhoeddwyd: (2020-07-01)

Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report
gan: Marco Ghezzi, et al.
Cyhoeddwyd: (2020-03-01)

Limbic encephalitis in metastatic malignant melanoma patient induced by PD-1 checkpoint inhibitor pembrolizumab
gan: Rozala Arko, et al.
Cyhoeddwyd: (2022-07-01)

Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations
gan: Ahmed Temirak, et al.
Cyhoeddwyd: (2025-02-01)

p53 Promotes Cytokine Expression in Melanoma to Regulate Drug Resistance and Migration
gan: Pinakin Pandya, et al.
Cyhoeddwyd: (2022-01-01)

Update on the treatment of BRAFmut metastatic melanoma and future perspectives
gan: Peter Mohr, et al.
Cyhoeddwyd: (2025-03-01)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
gan: Karam Khaddour, et al.
Cyhoeddwyd: (2021-06-01)

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study
gan: Igor V. Samoylenko, et al.
Cyhoeddwyd: (2024-10-01)

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
gan: Adi Kartolo, et al.
Cyhoeddwyd: (2022-03-01)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
gan: Simeng Zhang, et al.
Cyhoeddwyd: (2023-01-01)

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report
gan: Clara So, et al.
Cyhoeddwyd: (2022-05-01)

Braf protein mutation and its significancy within patients with melanoma
gan: Julia Kuchnicka, et al.
Cyhoeddwyd: (2022-08-01)

Treatment of Advanced Melanoma: Past, Present and Future
gan: Taku Fujimura, et al.
Cyhoeddwyd: (2020-09-01)

Comparison of Two Rapid Assays for the Detection of <i>BRAF</i> V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes
gan: Elodie Long-Mira, et al.
Cyhoeddwyd: (2022-03-01)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
gan: Walid Shalata, et al.
Cyhoeddwyd: (2023-02-01)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
gan: Nakul Dar, et al.
Cyhoeddwyd: (2023-08-01)

Tyrosine kinase inhibitors via nasogastric tube may resolve severe ileus secondary to melanoma: A case report
gan: Lena Groennendijk, et al.
Cyhoeddwyd: (2022-06-01)

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma
gan: Francesco Serra, et al.
Cyhoeddwyd: (2021-08-01)

Association between braf gene mutation status and clinical-morphological features of cutaneous melanoma
gan: O. I. Kit, et al.
Cyhoeddwyd: (2016-06-01)